Mollie Finkel, NP
Women's Health · Albany, NYNPI 1467704296
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by AstraZeneca at 52.4% of the total. Reporting peaked in 2021 at $3,697 and has fallen 53.0% since, to $1,737 in 2025. Among women's health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $156.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Corcept Therapeutics$1K
- GSK$1K
- Eisai Inc.$366
- AbbVie$300
- Genmab U.S., Inc.$184
- plus $342 from 4 others
What the payments were for
- Consulting fees$2,15331%
- Speaking & faculty fees$2,92042%
- Travel & lodging$591%
- Food & beverage$1,89527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $3,684 |
| Corcept Therapeutics | 4 | $1,097 |
| GSK | 16 | $1,053 |
| Eisai Inc. | 3 | $366 |
| AbbVie | 1 | $300 |
| Genmab U.S., Inc. | 2 | $184 |
| Merck | 2 | $120 |
| Pfizer | 1 | $118 |
| Immunogen, Inc. | 1 | $85 |
| Seagen Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,026 in reported general payments places this provider in the 95th percentile of 376 women's health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 14 | $108 |
| Ondansetron OdtOndansetron | 11 | $99 |
| Anastrozole | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other women's health in Albany
- Jenna HortonAlbany$37K
- Amy SantoroAlbany$3K
- Sophia FrontusBrooklyn$52K
- Austin JacobusNew York$51K
- Stacie WierWilliamsville$12K
- Jenna GoldsmithWilliamsville$9K
- Marjorie Seale-SimpsonMiddletown$6K
- Stacy GarrityNew York$5K
- Sarah WeldNew York$5K
- Kathleen CsillagNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.